Sign Out
There is insufficient information on the use of NOXAFIL in pregnant women. Studies in animals have shown reproductive toxicity. NOXAFIL has been shown to cause skeletal malformations in rats at exposures lower than those obtained at therapeutic doses in humans. In rabbits, NOXAFIL was embryotoxic at exposures greater than those obtained at therapeutic doses. The potential risk for humans is unknown. NOXAFIL should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential must be advised to always use effective contraceptive measure during treatment and for at least 2 weeks after completing therapy.
NOXAFIL is excreted into the milk of lactating rats. The excretion of NOXAFIL in human breast milk has not been investigated. NOXAFIL should not be used by nursing mothers unless the benefit clearly outweighs the risk to the infant.
Continue with Google